



EISAI'S ORAL ANTICOAGULo2LR.A(fjop5 D1en62.n(o2Lp010eN2(in0129#D02W
backdrop, the Japanese Mistry of Health, Labour and Welfare's Study Group on Un
Offlabel Drugs of High Medical Need "concluded that there is a substantial need to
available for use in pediatric patients and designated

In regards to pediatric indications for other cardiovascular products, Eisai received approval
antiarrhythmic agent Tambocor

® Tablets in Japan for treatment of arrhythmia in pediatric patients in
By 200 and submitted an Application Based on Public Knowledge in November 200 for the calcium
channel blocking antiarrhythmic agents Vasolan® Tablets and Vasolan® for Intravenous Injection. Having
received approval for pediatric use and administration of Warfarin® Tablets, Eisai seeks to establish
other drug therapies suitable for use in the pediatric setting and make further contributions to patients.

hehe

[Notes to editors]